These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 7539823)

  • 1. Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin.
    Siekierka JJ
    Immunol Res; 1994; 13(2-3):110-6. PubMed ID: 7539823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK 506 and rapamycin: molecular probes of T-lymphocyte activation.
    Bierer BE; Jin YJ; Fruman DA; Calvo V; Burakoff SJ
    Transplant Proc; 1991 Dec; 23(6):2850-5. PubMed ID: 1721296
    [No Abstract]   [Full Text] [Related]  

  • 3. Categorizing receptor-signaling pathways with FK 506 and rapamycin.
    Hultsch T; Hohman RJ
    Transplant Proc; 1991 Dec; 23(6):2961-3. PubMed ID: 1721328
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin.
    Zeevi A; Woan M; Yao GZ; Venkataramanan R; Todo S; Starzl TE; Duquesnoy RJ
    Transplant Proc; 1991 Dec; 23(6):2928-30. PubMed ID: 1721315
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction.
    Sigal NH; Dumont FJ
    Annu Rev Immunol; 1992; 10():519-60. PubMed ID: 1375473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunosuppressive macrolides FK-506 and rapamycin.
    Thomson AW
    Immunol Lett; 1991 Jul; 29(1-2):105-11. PubMed ID: 1717376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The actions of cyclosporin A and FK506 on T-lymphocyte activation.
    Mattila PS
    Biochem Soc Trans; 1996 Feb; 24(1):45-9. PubMed ID: 8674715
    [No Abstract]   [Full Text] [Related]  

  • 8. Molecular mechanisms of new immunosuppressants.
    Halloran PF
    Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modes of action of FK506, cyclosporin A, and rapamycin.
    Morris R
    Transplant Proc; 1994 Dec; 26(6):3272-5. PubMed ID: 7527964
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect.
    Cooper MH; Gregory SH; Thomson AW; Fung JJ; Starzl TE; Wing EJ
    Transplant Proc; 1991 Dec; 23(6):2957-8. PubMed ID: 1721326
    [No Abstract]   [Full Text] [Related]  

  • 11. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.
    Dumont FJ; Melino MR; Staruch MJ; Koprak SL; Fischer PA; Sigal NH
    J Immunol; 1990 Feb; 144(4):1418-24. PubMed ID: 1689353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes.
    Dumont FJ; Kastner C; Iacovone F; Fischer PA
    J Pharmacol Exp Ther; 1994 Jan; 268(1):32-41. PubMed ID: 7507994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of T and B lymphocyte proliferation by rapamycin.
    Kay JE; Kromwel L; Doe SE; Denyer M
    Immunology; 1991 Apr; 72(4):544-9. PubMed ID: 1709916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis.
    Staruch MJ; Sigal NH; Dumont FJ
    Int J Immunopharmacol; 1991; 13(6):677-85. PubMed ID: 1721613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.
    Dumont FJ; Staruch MJ; Koprak SL; Siekierka JJ; Lin CS; Harrison R; Sewell T; Kindt VM; Beattie TR; Wyvratt M
    J Exp Med; 1992 Sep; 176(3):751-60. PubMed ID: 1380976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK-506, and rapamycin.
    Duncan JI
    J Invest Dermatol; 1994 Jan; 102(1):84-8. PubMed ID: 7507155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A.
    Metcalfe S; Milner J
    Transplantation; 1991 Jun; 51(6):1318-20. PubMed ID: 1710844
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanism of action of rapamycin (Sirolimus, Rapamune).
    Molnar-Kimber KL
    Transplant Proc; 1996 Apr; 28(2):964-9. PubMed ID: 8623482
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation.
    Bierer BE; Schreiber SL; Burakoff SJ
    Eur J Immunol; 1991 Feb; 21(2):439-45. PubMed ID: 1705513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of transcription factor NF kappa B in Jurkat cells is inhibited selectively by FK 506 in a signal-dependent manner.
    Su MS; Semerjian A
    Transplant Proc; 1991 Dec; 23(6):2912-5. PubMed ID: 1721310
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.